top of page


AstraZeneca acquires Omniose to expand bacterial conjugate vaccine technology
AstraZeneca has completed its acquisition of US vaccine technology company Omniose, adding a proprietary bacterial bioconjugation platform to strengthen development of vaccines against serious infections and antimicrobial-resistant pathogens.

nuaxia
6 days ago2 min read


SynAct Pharma signs Brazilian resomelagon dengue partnership with Hipolabor on 50-50 profit-sharing terms
SynAct Pharma has formalised a Brazilian partnership with Hipolabor to develop and commercialise investigational resomelagon for dengue treatment under a 50-50 cost and profit-sharing structure.

nuaxia
Oct 282 min read


FDA approves GSK Hibsago bepirovirsen as first antisense treatment for chronic hepatitis B
The FDA has approved GSK's Hibsago as the first antisense oligonucleotide treatment for chronic hepatitis B, offering eligible patients a new approach to sustained viral control.

nuaxia
Oct 212 min read


FDA approves Hovilpri as novel oral treatment for refractory herpes simplex infections in immunocompromised adults
The FDA has approved Hovilpri, a novel oral helicase-primase inhibitor for refractory mucocutaneous herpes simplex virus infections in immunocompromised adults.

nuaxia
Oct 122 min read


US Infectious Disease Physician Compensation Reaches $337,353 in Doximity’s 2026 Report
Average annual compensation for US infectious disease physicians reached $337,353 in Doximity’s 2026 Physician Compensation Report, providing an updated national benchmark for physicians working in infectious disease.

nuaxia
Sep 73 min read


Eli Lilly Builds Infectious Disease Platform with Three-Acquisition Strategy
The company expands into vaccine-led prevention as pharma shifts focus toward long-term disease risk reduction driven by infection-linked chronic outcomes and antimicrobial resistance.

nuaxia
May 303 min read
bottom of page